Regulatory Roundup: EMA monitors Japanese-manufactured medicines following radiation leak from nuclear power plant - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: EMA monitors Japanese-manufactured medicines following radiation leak from nuclear power plant

ePT--the Electronic Newsletter of Pharmaceutical Technology

EMA is working with its European and international regulatory partners to monitor and evaluate “the possible risk of radioactive contamination of medicines manufactured in Japan following the radiation leak from the Fukushima Daiichi nuclear power plant,” according to a recent EMA press release. To date, information has shown that the risk to public and animal health is small, but EMA is taking a precautionary approach, which includes putting certain measures into place for food and animal feed throughout Europe. The ultimate responsibility for safety, efficacy, and quality of products manufactured in Japan, says the release, is the holder of the product marketing authorization. Marketing authorization holders are therefore being asked to test their products for radionuclides iodine-131, caesium-134, and caesium-137 prior to exporting products out of Japan.

FDA has posted on its website the minutes from meetings between the agency and industry regarding the Prescription Drug User Fee Act (PDUFA) reauthorization. The meetings took place in January and February of this year.

FDA and EMA released on May 16, 2011, a document about how the agencies plan to work together on parallel reviews of quality-by-design based new drug applications as part of their ongoing pilot program. The document provides advice to applicants on the background and objectives of the pilot, as well on the steps that will be taken to coordinate the parallel review and related GMP inspections.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here